Published in Semin Hematol on July 01, 2012
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One (2013) 0.86
Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev (2013) 0.82
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. Front Pharmacol (2015) 0.78
Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells. Cell Commun Signal (2014) 0.78
The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone (2016) 0.75
E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models. J Cell Physiol (2015) 0.75
Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res (2017) 0.75
Increased PLEKHO1 within osteoblasts suppresses Smad-dependent BMP signaling to inhibit bone formation during aging. Aging Cell (2017) 0.75
Marrow stromal cells as stem cells for nonhematopoietic tissues. Science (1997) 17.06
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J (1997) 12.97
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell (2005) 8.16
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Regulation of bone mass by Wnt signaling. J Clin Invest (2006) 5.59
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol (2002) 3.09
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J (2003) 2.30
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci (2006) 2.18
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood (2008) 2.05
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 1.93
Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem (2002) 1.91
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood (2006) 1.77
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood (2007) 1.75
Wnt signaling in B-cell neoplasia. Oncogene (2003) 1.73
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res (2008) 1.58
Wnts induce migration and invasion of myeloma plasma cells. Blood (2005) 1.58
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia (2008) 1.56
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone (2007) 1.50
Control of RANKL gene expression. Bone (2009) 1.47
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood (2003) 1.44
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol (1989) 1.33
Pathogenesis of myeloma bone disease. Blood Cells Mol Dis (2004) 1.33
Bortezomib inhibits human osteoclastogenesis. Leukemia (2007) 1.30
Myeloma bone disease and proteasome inhibition therapies. Blood (2007) 1.29
Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol (2004) 1.27
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol (2006) 1.27
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood (2009) 1.25
Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons. J Biol Chem (2006) 1.25
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer (2006) 1.21
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
RANK ligand and osteoprotegerin in myeloma bone disease. Blood (2002) 1.13
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol (2008) 1.13
Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol (2008) 1.10
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun (2005) 1.07
Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol (2009) 1.05
Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood (1995) 1.04
Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol (2003) 1.03
Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma (2006) 1.01
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res (2008) 0.95
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia (2005) 0.91
Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma (2007) 0.90
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol (2010) 0.89
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol (2009) 0.86
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol (2011) 0.83
Myeloma affects both the growth and function of human osteoblast-like cells. Clin Exp Metastasis (1992) 0.79
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
The molecular classification of multiple myeloma. Blood (2006) 8.77
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis (2010) 2.10
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood (2008) 2.05
Nephrocutaneous bypass in ureteral obstruction. Urology (2010) 2.04
Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res (2004) 1.98
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Familial myeloma. N Engl J Med (2008) 1.96
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood (2012) 1.93
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 1.93
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med (2004) 1.85
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol (2010) 1.84
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A (2010) 1.78
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol (2002) 1.74
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res (2009) 1.72
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood (2005) 1.71
Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis (2011) 1.70
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol (2010) 1.66
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood (2002) 1.65